Program
chloroprocaine
Also written as “Chloroprocaine Ophthalmic Gel 3% (IHEEZO)”, “Chloroprocaine 1% Injectable Solution” and “Chloroprocaine 2% Injectable Solution”.
Its studies are mostly in Macular Degeneration · Hernia, Inguinal · Cataract, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sintetica | 60 open or running | phase 3since Feb 20, 2015 | Feb 20, 2015 | none ahead |
| Harrow | 21 open or running | phase 4since Jun 9, 2023 | Jun 9, 2023 | none ahead |
Also a collaborator on its studies: cross-research-s-a and cross-s-a.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 20, 2015First study: phase 3 study in Axillary Nerve BlockNew to SinteticaSintetica · NCT02385097 · 211 enrolled · Switzerland
- Jun 2, 2015Phase 2 study in Short Duration Lower Limb Surgery Via Spinal AnaesthesiaSintetica · NCT02481505 · 45 enrolled · Italy
- Aug 29, 2016Phase 3 study in Unplanned Caesarean SectionSintetica · NCT02919072 · 16 enrolled · Belgium
- Mar 20, 2019Phase 2 study in Hernia, InguinalSintetica · NCT03918798 · 164 enrolled · Italy, Spain
- Dec 15, 2020Phase 3 study in CataractSintetica · NCT04685538 · 338 enrolled · Italy, Slovakia, Spain
- Jun 6, 2023Phase 3 study in Local AnestheticSintetica · NCT05926258 · 74 enrolled · Italy
- Jun 9, 2023Harrow's first study: phase 4 study in AntisepticNew to HarrowHarrow · NCT05934253 · 100 enrolled · United States
- Feb 25, 2026Phase 4 study in Macular DegenerationHarrow · NCT07456826 · 236 planned · United States
TargetBeta
“Sodium channel alpha subunit blocker”ChEMBL 37, by rule
Other programs on the same 10 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Lidocainerule | Keenova Therapeutics | phase 4 | 63 |
| Lamotriginerule | GlaxoSmithKline | phase 4 | 61 |
| Carbamazepinerule | grin-therapeutics-inc | phase 4 | 21 |
| Dronedaronerule | Sanofi | phase 4 | 18 |
| Riluzolerule | Sanofi | phase 4 | 6 |
| Prilocainerule | Haisco Pharmaceutical Group | phase 4 | 2 |
| Carticainerule | Laboratoires Thea | phase 4 | 1 |
| Ropivacainerule | painreform-ltd | phase 3 | 17 |
| Phenytoinrule | Viatris | phase 3 | 10 |
| rufinamiderule | Eisai | phase 3 | 7 |
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07456826Macular Degeneration · United States | 4 | By invitation | Harrow | Aug 2026 | 236 |
| NCT05934253Antiseptic · United States | 4 | Completed | Harrow | Jan 15, 2024 | 100 |
| NCT05926258Local Anesthetic · Italy | 3 | Completed | Sintetica | Mar 13, 2025 | 74 |
| NCT04685538Cataract · Italy, Slovakia, Spain | 3 | Completed | Sintetica | Mar 1, 2021 | 338 |
| NCT03918798Hernia, Inguinal · Italy, Spain | 2 | Completed | Sintetica | Oct 17, 2025 | 164 |
| NCT02919072Unplanned Caesarean Section · Belgium | 3 | Terminated | Sintetica | Jun 2021 | 16 |
| NCT02481505Short Duration Lower Limb Surgery Via Spinal Anaesthesia · Italy | 2 | Completed | Sintetica | Nov 2015 | 45 |
| NCT02385097Axillary Nerve Block · Switzerland | 3 | Completed | Sintetica | May 2017 | 211 |
How it is read
Names in the registry
- “Chloroprocaine Ophthalmic Gel 3% (IHEEZO)”, 1 entry
- “Chloroprocaine 1% Injectable Solution”, 1 entry
- “Chloroprocaine 2% Injectable Solution”, 1 entry
- “Chloroprocaine 3% eye gel”, 1 entry
- “Chloroprocaine ophthalmic gel 3%”, 1 entry
Conditions, from the studies’ own filings
- Macular Degeneration, 1 study
- Hernia, Inguinal, 1 study
- Cataract, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.